Empowered Funds LLC Takes $3.16 Million Position in Novo Nordisk A/S $NVO

Empowered Funds LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 45,470 shares of the company's stock, valued at approximately $3,157,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Peloton Wealth Strategists purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $880,000. Ascent Group LLC raised its position in shares of Novo Nordisk A/S by 30.6% during the 1st quarter. Ascent Group LLC now owns 26,532 shares of the company's stock valued at $1,842,000 after buying an additional 6,218 shares in the last quarter. Signature Estate & Investment Advisors LLC raised its position in shares of Novo Nordisk A/S by 30.6% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 8,221 shares of the company's stock valued at $571,000 after buying an additional 1,925 shares in the last quarter. Guardian Partners Inc. raised its position in shares of Novo Nordisk A/S by 1.1% during the 1st quarter. Guardian Partners Inc. now owns 128,738 shares of the company's stock valued at $8,940,000 after buying an additional 1,347 shares in the last quarter. Finally, Sepio Capital LP raised its position in shares of Novo Nordisk A/S by 37.5% during the 1st quarter. Sepio Capital LP now owns 27,359 shares of the company's stock valued at $1,900,000 after buying an additional 7,455 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on NVO shares. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Dbs Bank upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, August 22nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday. Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Wednesday, August 20th. Finally, Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $54.94 on Friday. The firm has a market cap of $245.31 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 2.06 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $138.22. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company's fifty day simple moving average is $57.96 and its two-hundred day simple moving average is $66.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.